Etiology and Microbiology of Bacterial Urinary Tract Infection

1. Overview

2. Routes of Infection

3. Etiologic Agents

Uncomplicated UTI

Complicated UTI

• Comprehensive Clinical Nephrology, 7th Ed., Table 53.2

4. Uropathogenic E. coli (UPEC) - Microbiology and Virulence

• Jawetz, Melnick & Adelberg's Medical Microbiology, 28th Ed., p. 244
• Comprehensive Clinical Nephrology, 7th Ed., p. 757

5. Characteristics of Individual Organisms

• Urease producer - splits urea to ammonia, alkalinizing urine
• Creates conditions favoring struvite (triple phosphate) stone formation
• Stones serve as a persistent nidus for infection
• More common in catheterized patients and males with complicated UTI

• Produces a large polysaccharide capsule (anti-phagocytic)
• Increasingly important as ESBL-producing strains (particularly K. pneumoniae carbapenemase, KPC)
• More prevalent in hospital-acquired and complicated UTI

• Virtually all infections are complicated (catheter-associated, structural abnormality)
• Intrinsic resistance to many antibiotics; forms biofilms on catheters
• Associated with high-risk nosocomial settings

• More common in complicated UTI, instrumented patients, and after antibiotic therapy
• E. faecium increasingly resistant (VRE)

• UTI usually secondary to hematogenous spread from a distant focus (bacteremia)
• Should prompt investigation for bacteremia if isolated in urine
• Also seen post-instrumentation

• Coagulase-negative staphylococcus
• Unique niche: sexually active young women (15-30 years), particularly in autumn/winter
• Has specific adhesins for uroepithelial cells
• Intrinsically resistant to novobiocin (differentiates it from other CoNS)
• Rarely causes pyelonephritis

6. Host Factors Modulating UTI Risk

• Behavioral: sexual intercourse, spermicide use, recent antibiotic use, suboptimal voiding
• Genetic: nonsecretor of ABO blood group antigens, P1 blood group phenotype, reduced CXCR1 expression, prior recurrent UTI
• Biologic: estrogen deficiency (postmenopausal women), glycosuria (including from SGLT-2 inhibitors), pregnancy

• Normal vaginal flora (lactobacilli)
• Mechanical flushing during micturition
• Intact host immune response
• Longer urethra and drier periurethral environment (males)

7. Complicated UTI - Expanded Pathogen Diversity

• Cause obstruction or stasis of urine flow
• Bypass host defense mechanisms (indwelling catheters, stents)
• Provide a persistent nidus (stones, biofilm on hardware)
• Compromise host immunity (diabetes, transplantation, immunosuppression)

8. Summary Table: Key Points

• Comprehensive Clinical Nephrology, 7th Edition (Drekonja & Hooton, Chapter 53)
• Jawetz, Melnick & Adelberg's Medical Microbiology, 28th Edition
• Campbell-Walsh-Wein Urology
• Rosen's Emergency Medicine

Etiology of Urinary Tract Infection - In Detail

1. General Principles

2. Etiologic Agents in Uncomplicated UTI

• Comprehensive Clinical Nephrology, 7th Ed., Table 53.2; Goldman-Cecil Medicine, Table 263-2

3. Etiologic Agents in Complicated UTI

• Brenner & Rector's The Kidney; Goldman-Cecil Medicine; Tintinalli's Emergency Medicine

4. Organism-by-Organism Detail

4.1 Escherichia coli - The Dominant Uropathogen

4.2 Staphylococcus saprophyticus

• Second most common cause of uncomplicated UTI in young women (up to 15-20%)
• Coagulase-negative staphylococcus with specific adhesins for uroepithelial cells
• Seasonality: more common in spring/summer months (also reported in late summer/early fall)
• Identification tip: distinguished from other coagulase-negative staphylococci by resistance to novobiocin
• Nitrite test is negative (does not reduce nitrate - important dipstick pitfall)
• Only rarely causes acute pyelonephritis
• Isolation in the context of uncomplicated UTI in young women is genuine infection, not contamination

4.3 Proteus mirabilis

• Gram-negative bacillus; a urease-producer - splits urea to ammonia
• Ammonia alkalinizes the urine (pH ≥ 7)
• Alkaline conditions promote precipitation of struvite (triple phosphate: magnesium ammonium phosphate) calculi
• Stones can grow to become large staghorn calculi completely obstructing the renal pelvis
• Stones serve as a persistent nidus for infection - difficult to eradicate without stone removal
• Also elaborates urease-based biofilm that can obstruct catheters (~80% of obstructed urinary catheters are attributable to P. mirabilis)
• More common in catheterized patients and males with complicated UTI
• Nitrite test is positive (reduces nitrate)

4.4 Klebsiella spp.

• Occasionally causes community-acquired uncomplicated UTI
• More often signifies complicated UTI - especially in patients who have received multiple antibiotic courses, have indwelling catheters, or have undergone urologic intervention
• Possesses a thick polysaccharide capsule conferring anti-phagocytic properties
• ESBL-producing Klebsiella is increasingly problematic in hospital-acquired UTI
• Klebsiella pneumoniae carbapenemase (KPC) isolates are particularly challenging

4.5 Pseudomonas aeruginosa

• Virtually all P. aeruginosa UTIs are complicated (catheter-associated, structural abnormality, neutropenic, transplant)
• Intrinsic resistance to many first-line antibiotics (narrow-spectrum penicillins, most cephalosporins, trimethoprim)
• Forms robust biofilms on catheters and devices
• Associated with high-risk nosocomial settings (ICU, urology wards, long-term care)
• Requires anti-pseudomonal agents (piperacillin-tazobactam, cefepime, carbapenems, ciprofloxacin, aminoglycosides)

4.6 Enterococcus faecalis / faecium

• Presence in urine typically correlates with prior antibiotic therapy, urologic instrumentation, or obstructive uropathy
• Seldom causes acute symptomatic UTI in otherwise healthy individuals
• More common in older men with benign prostatic hyperplasia or post-urologic procedures
• Clinical significance: Enterococcal UTI is a risk factor for enterococcal endocarditis - always consider in at-risk patients
• E. faecium increasingly carries vancomycin resistance (VRE)
• Intrinsically resistant to cephalosporins, clindamycin, and low-level aminoglycosides

4.7 Staphylococcus aureus

• Isolation in the urine most often represents "spillover" from bacteremia rather than primary urinary tract infection
• S. aureus UTI should prompt investigation for bacteremia and distant seeding (endocarditis, vertebral osteomyelitis)
• Can also indicate renal abscess (carbuncle) as a source
• Also seen post-urological instrumentation, especially in older men with obstructive uropathy
• Occasionally community-acquired, particularly in diabetics

4.8 Group B Streptococcus (Streptococcus agalactiae)

• Rarely causes cystitis in healthy young women
• Clinically important in pregnant women (risk of chorioamnionitis, neonatal sepsis)
• Can cause symptomatic UTI in older patients with risk factors for complicated UTI
• Routine screening and treatment of GBS bacteriuria in pregnancy is recommended

4.9 Staphylococcus epidermidis

• Frequent contaminant in urine cultures due to heavy skin flora presence
• Symptomatic UTI occurs mainly in persons with indwelling urinary catheters
• Usually not treated unless clear evidence of catheter-associated infection

4.10 Uncommon but Clinically Important Organisms

4.11 Culture-Negative UTI ("Urethral Syndrome")

• Ureaplasma urealyticum
• Chlamydia trachomatis (urethritis, sexually transmitted)
• Mycoplasma hominis/genitalium

4.12 Fungal UTI

• Candida albicans and other Candida spp. are the most common cause of fungal UTI
• Risk factors: diabetes mellitus, indwelling urinary catheter, prior broad-spectrum antibiotic therapy
• Patients often asymptomatic; treatment not always required
• In severe cases: fungus balls can obstruct ureters or renal pelvis
• Candida UTI accounts for an increasing proportion of nosocomial UTIs

4.13 Viral UTI

• Adenoviruses (types 11 and 21) cause acute hemorrhagic cystitis, mainly in children, young adults, and immunosuppressed patients
• This form of hemorrhagic cystitis is not caused by bacteria

5. Etiology by Clinical Setting

6. Key Concept: Biofilm and Catheter-Associated UTI

1. A conditioning layer of host proteins coats the catheter immediately on insertion
2. Organisms adhere to this layer (from periurethral flora, drainage bag, or external sources)
3. Bacteria elaborate extracellular polysaccharide matrix, incorporating Tamm-Horsfall protein, Ca²⁺, Mg²⁺
4. Biofilm ascends along the catheter interior and exterior, reaching the bladder within days
5. Bacteriuria accumulates at 3-7% per day, reaching ~100% prevalence by 30 days of catheterization
6. Initially single organism; polymicrobial flora is invariable in mature biofilms on chronic devices
7. Urease-producing organisms (P. mirabilis, K. pneumoniae, M. morganii, P. stuartii) persist longest and create crystalline biofilms that obstruct catheters
8. 34-42% of ureteral stents are colonized at removal; >50% of organisms in stent biofilm are not detected by simultaneous urine culture

• Brenner & Rector's The Kidney; Goldman-Cecil Medicine

7. Organisms Considered Contaminants in Healthy Women (Not True Uropathogens)

• Lactobacillus spp.
• Gardnerella vaginalis
• Coagulase-negative staphylococci (except S. saprophyticus)
• Corynebacterium spp. (ordinary diphtheroids)
• Streptococcus (non-enterococcal)
• Anaerobes

Summary Diagram

• Comprehensive Clinical Nephrology, 7th Ed. (Drekonja & Hooton, Ch. 53)
• Goldman-Cecil Medicine, Ch. 263 - Table 263-2
• Smith & Tanagho's General Urology, 19th Ed.
• Brenner & Rector's The Kidney (Complicated UTI Microbiology)
• Jawetz, Melnick & Adelberg's Medical Microbiology, 28th Ed.
• Textbook of Family Medicine, 9th Ed., Table 15-8
• Quick Compendium of Clinical Pathology, 5th Ed.
• Tintinalli's Emergency Medicine
• Tietz Textbook of Laboratory Medicine, 7th Ed.

Bacteria Causing UTI - Detailed Individual Profiles

Overview Frequency Table

GRAM-NEGATIVE ORGANISMS

1. Escherichia coli

Classification

• Family Enterobacteriaceae; Gram-negative rod (bacillus)
• Facultative anaerobe; ferments lactose
• Serotyped by O (somatic), K (capsular), H (flagellar) antigens

Frequency and Significance

• Most common cause of UTI overall - accounts for ~90% of first UTIs in young women and 70-95% of uncomplicated UTIs
• Remains dominant in complicated UTI (21-54%), though less virulent strains predominate
• Single most important uropathogen across all clinical settings

Why E. coli?

Virulence Factors in Detail

• Pore-forming cytotoxin
• Lyses erythrocytes AND leukocytes (neutrophils, macrophages)
• Initiates tissue invasion
• Releases iron from lysed cells, making iron available for bacterial metabolism
• Most uropathogenic E. coli strains produce hemolysin

• Anti-phagocytic - protects bacteria from neutrophil phagocytosis
• Confers serum resistance (complement evasion)
• Pyelonephritis-causing strains especially express K antigen

• Iron-chelating siderophore
• Competes with host iron-binding proteins (transferrin, lactoferrin)
• Acquires iron in the iron-poor urinary environment

• Allows survival in bloodstream if bacteremia occurs
• Important for hematogenous spread

Intracellular Invasion - The Key to Recurrence

1. FimH adhesin at the tip of type 1 pili binds bladder epithelium
2. Host cell signaling is activated: focal adhesion kinase, PI-3 kinases, α-actinin, and vinculin are recruited
3. Localized actin rearrangement causes membrane zippering around the bound bacterium
4. Bacteria are engulfed and enter the cytoplasm
5. Intracellular bacteria mature into biofilms within pod-like bulges on the urothelial surface
6. Pods contain bacteria encased in polysaccharide-rich matrix surrounded by a uroplakin shell
7. This intracellular reservoir is protected from antibiotics and immune defenses - the mechanism underlying persistence and recurrence of UTI

Pandemic Clone: E. coli O25b/ST131

• Emerged over the last decade as a globally dominant uropathogen
• Success due to acquisition of plasmid-mediated resistance:
  • ESBL (extended-spectrum beta-lactamase) production - resistance to most beta-lactams
  • Fluoroquinolone resistance
  • Aminoglycoside resistance
• Responsible for the dramatic global rise in multidrug-resistant community UTI

Dipstick Correlation

• Nitrite positive: E. coli reduces urinary nitrate to nitrite (positive test)
• Leukocyte esterase positive: from pyuria

2. Staphylococcus saprophyticus

Classification

• Gram-positive coccus in clusters
• Coagulase-negative staphylococcus (CoNS)
• Non-hemolytic on blood agar

Frequency and Setting

• Second most common cause of uncomplicated UTI in young women (5-20%; up to 15% of cases)
• Unique niche: sexually active young women aged 15-30 years
• Seasonal pattern: more common in spring and summer months (some sources: late summer/early fall)
• Only rarely causes acute pyelonephritis
• Rarely causes UTI in men or elderly patients

Virulence

• Possesses specific adhesins for uroepithelial cells - distinguishes it from other CoNS
• Surface adhesins and production of extracellular polysaccharide biofilm contribute to colonization

Identification Pearl

• Differentiated from all other CoNS by resistance to novobiocin (a simple lab test)
  • S. saprophyticus: novobiocin-resistant
  • S. epidermidis and most other CoNS: novobiocin-sensitive

Dipstick Pearl

• Nitrite negative - does not reduce nitrate to nitrite
• Leukocyte esterase positive
• A young woman with classic UTI symptoms + negative nitrite + positive leukocyte esterase should raise suspicion for S. saprophyticus

3. Proteus mirabilis

Classification

• Gram-negative rod; Family Enterobacteriaceae
• Highly motile (swarming on agar)
• Urease-producer: the cardinal feature

Frequency

• 1-2% of uncomplicated UTIs
• 1-10% of complicated UTIs
• More common in males, catheterized patients, long-term care

The Urease-Struvite Axis - The Defining Feature

1. Urease enzyme hydrolyzes urea → ammonia (NH₃) + CO₂
2. Ammonia dissolves in water → ammonium (NH₄⁺), highly alkalinizing
3. Urine pH rises to ≥ 7 (supraphysiologic; normal urine pH ~5-6)
4. Alkaline urine promotes precipitation of magnesium ammonium phosphate (struvite) = "triple phosphate" stones
5. Struvite stones grow rapidly, can fill the entire renal pelvis = staghorn calculi
6. Stones act as a persistent nidus for infection - bacteria hide within stone matrix, protected from antibiotics
7. Effective eradication requires both antibiotic therapy AND stone removal

Biofilm and Catheter Obstruction

• P. mirabilis produces copious biofilm on urinary catheters
• Urease creates an alkaline environment within the biofilm → crystalline deposits of calcium/magnesium
• ~80% of all obstructed urinary catheters are caused by P. mirabilis crystalline biofilm
• Also associated with biofilm on ureteral stents and nephrostomy tubes

Other Virulence Factors

• Flagella (swarming motility): enables rapid spread along catheter surfaces
• IgA protease: cleaves secretory IgA, impairing mucosal immunity
• Fimbriae (MR/P - mannose-resistant/Proteus-like fimbriae and MR/K fimbriae) for adhesion

Dipstick

• Nitrite positive (reduces nitrate)
• Urine pH consistently high (≥7)

4. Klebsiella pneumoniae (and other Klebsiella spp.)

Classification

• Gram-negative rod, non-motile; Family Enterobacteriaceae
• Lactose-fermenter
• Mucoid colonies on agar due to thick polysaccharide capsule

Frequency

• 1-2% of uncomplicated community UTIs
• 2-17% of complicated UTIs
• More prevalent in hospital-acquired UTI, prior antibiotic exposure, instrumented patients

Key Virulence Features

• Large polysaccharide (K) capsule: anti-phagocytic; resists complement; gives mucoid "string test" positive colonies
• Fimbriae (type 1 and type 3/MR/K): adhesion to uroepithelium and bladder mucosa
• Siderophores (enterobactin, aerobactin): iron acquisition

Clinical Context

• Occasionally causes community-acquired uncomplicated UTI in healthy women
• Presence of Klebsiella in urine generally indicates complicated UTI: prior antibiotics, indwelling catheter, urologic intervention
• K. pneumoniae is a leading urease-producer in catheter-associated biofilm (alongside Proteus)
• Hypervirulent Klebsiella (hvKp): emerging variant causing severe primary liver abscess with metastatic UTI, endophthalmitis in Asian populations (diabetics)

Antibiotic Resistance - The Major Clinical Concern

• ESBL-producing Klebsiella: increasingly common in community and hospital settings; resistant to most penicillins and cephalosporins
• KPC (Klebsiella pneumoniae carbapenemase): resistant to carbapenems; extremely difficult to treat
• Healthcare settings with high antibiotic use are reservoirs for these MDR strains

5. Enterobacter species (E. cloacae, E. aerogenes / Klebsiella aerogenes)

Classification

• Gram-negative rods; Family Enterobacteriaceae
• Motile; lactose-fermenting

Frequency

• <1% uncomplicated UTI
• 2-10% complicated/hospital-acquired UTI

Key Features

• Predominantly a nosocomial uropathogen - rarely causes community-acquired UTI
• Intrinsically resistant to ampicillin and first-generation cephalosporins
• Possess inducible AmpC beta-lactamases - can de-repress resistance during cephalosporin therapy (the "ESCAPPM" organisms - E for Enterobacter)
• Clinical concern: patient initially appears to respond to a 3rd-generation cephalosporin, then fails as AmpC is induced
• Associated with ICU patients, transplant recipients, those on broad-spectrum antibiotics

6. Citrobacter species

Classification

• Gram-negative rods; Family Enterobacteriaceae
• Can use citrate as sole carbon source (hence the name)

Frequency

• <1% uncomplicated UTI
• ~5% complicated/nosocomial UTI

Key Features

• Nosocomial uropathogen; rarely community-acquired
• Citrobacter freundii can produce extended-spectrum beta-lactamases
• Some strains produce AmpC beta-lactamases
• Associated with catheter-associated UTI and bacteremia in immunocompromised patients

7. Pseudomonas aeruginosa

Classification

• Gram-negative non-fermenting rod (non-Enterobacteriaceae)
• Oxidase-positive; motile with polar flagellum
• Characteristic fruity/grape-like odor; blue-green pigment (pyocyanin + pyoverdine) on culture

Frequency

• <1% of uncomplicated UTI (virtually never)
• 2-19% of complicated UTI - especially ICU, catheterized, neutropenic patients

Virtually All P. aeruginosa UTIs are Complicated

Virulence

• Alginate biofilm: forms extremely tough biofilm on catheters and devices - protected from antibiotics and host defenses
• Exotoxin A: inhibits protein synthesis (similar mechanism to diphtheria toxin)
• Proteases (alkaline protease, LasB elastase): degrade host immune proteins
• Flagella and pili (type IV): motility and adhesion
• Pyocyanin: reactive oxygen species generator - toxic to host cells

Intrinsic and Acquired Resistance

• Intrinsic resistance: most penicillins, most cephalosporins (except ceftazidime, cefepime), many carbapenems (except imipenem, meropenem, doripenem), trimethoprim
• Acquired resistance: via multiple mechanisms (efflux pumps, OprD porin loss, AmpC induction, ESBLs)
• Requires anti-pseudomonal agents: piperacillin-tazobactam, ceftazidime, cefepime, carbapenems, ciprofloxacin, levofloxacin, aminoglycosides
• XDR (extensively drug-resistant) strains: managed with newer agents (ceftolozane-tazobactam, ceftazidime-avibactam, imipenem-cilastatin-relebactam, cefiderocol)

8. Proteus vulgaris / Morganella morganii / Providencia stuartii

Shared Features

• All are urease-producing Gram-negative rods
• All associated with long-term indwelling urinary catheters
• All produce crystalline biofilm leading to catheter obstruction
• All are more resistant to antibiotics than E. coli or Proteus mirabilis

Individual Notes

9. Serratia marcescens

Classification

• Gram-negative rod; Enterobacteriaceae
• Produces red pigment (prodigiosin) on some media at room temperature

Context

• Primarily a nosocomial uropathogen - nursing homes, ICU, catheterized patients
• Very resistant: intrinsic resistance to ampicillin, first-generation cephalosporins, colistin
• Produces extended-spectrum beta-lactamases; AmpC beta-lactamases
• Associated with outbreaks in healthcare settings
• Can cause bacteremia/sepsis from urinary source in immunocompromised patients

10. Stenotrophomonas maltophilia / Acinetobacter baumannii

Context

• Both are non-fermenting Gram-negative rods (like Pseudomonas)
• Occur in the context of very frequent UTI recurrences, prolonged hospitalization, multiple prior antibiotic courses
• S. maltophilia: intrinsically resistant to carbapenems; treated with TMP-SMX
• A. baumannii: major carbapenem-resistant nosocomial pathogen; UTI mainly in ICU patients

GRAM-POSITIVE ORGANISMS

11. Enterococcus faecalis and Enterococcus faecium

Classification

• Gram-positive cocci in pairs and chains
• Catalase-negative; facultative anaerobes
• Can grow in 6.5% NaCl, at 10°C and 45°C, and bile-containing media (distinguishes from streptococci)

Frequency

• 1-2% of uncomplicated UTI in healthy non-hospitalized women
• 1-23% of complicated UTI (especially post-procedure, obstructive, diabetic)

Clinical Context for Enterococcal UTI

• Prior antibiotic therapy (especially broad-spectrum agents with anaerobic activity: clindamycin, metronidazole, piperacillin-tazobactam)
• Urologic instrumentation (cystoscopy, stent placement, TURP)
• Obstructive uropathy (BPH in elderly men)
• Diabetes mellitus
• Prolonged hospitalization

Critical Clinical Warning - Endocarditis Risk

• Enterococcal UTI is a risk factor for enterococcal endocarditis
• ~25% of patients with E. faecalis bacteremia have definitive endocarditis
• ~50% of patients with E. faecalis endocarditis have an underlying colorectal neoplasm
• Enterococci are the third most common cause of infective endocarditis overall
• Left-sided endocarditis (mitral valve) most common; subacute presentation

E. faecalis vs. E. faecium

Antibiotic Resistance

• Intrinsic resistance: cephalosporins, clindamycin, TMP-SMX, low-level aminoglycosides
• Acquired resistance: vancomycin resistance (VRE) - especially E. faecium; high-level aminoglycoside resistance
• VRE risk factors: prolonged broad-spectrum antibiotics, hematologic malignancy, HIV, chronic renal failure, liver transplantation

Dipstick

• Nitrite negative (does not reduce nitrate)
• May be missed on standard dipstick-only screening

12. Staphylococcus aureus

Classification

• Gram-positive coccus in grape-like clusters
• Coagulase-positive; catalase-positive
• Beta-hemolytic on blood agar

Frequency in UTI

• <1% of uncomplicated UTI
• 1-2% of complicated UTI
• Uncommon uropathogen overall

Why S. aureus in Urine Demands Attention

1. "Spillover" from bacteremia - bacteria seeding the kidney from the bloodstream during a distant primary infection (endocarditis, IV catheter infection, skin/soft tissue infection)
2. Renal abscess (carbuncle) - a focal intrarenal suppurative collection discharging into the collecting system
3. Post-urological instrumentation - especially in older men with obstructive uropathy
4. Hematogenous seeding from a primary distant focus in diabetics

Clinical Rule

Isolating S. aureus from urine should always prompt investigation for concurrent bacteremia, endocarditis, or renal abscess - before attributing it to a primary UTI.

Antibiotic Resistance

• MRSA (methicillin-resistant S. aureus): treated with vancomycin, linezolid, daptomycin
• Community MRSA and hospital MRSA: different resistance profiles

13. Staphylococcus epidermidis (and other CoNS excluding S. saprophyticus)

Classification

• Gram-positive cocci; coagulase-negative
• Novobiocin-sensitive (key distinction from S. saprophyticus)

Context

• Most often a contaminant in voided midstream urine specimens due to ubiquitous skin colonization
• Genuine symptomatic UTI occurs mainly in persons with indwelling urinary catheters
• Forms biofilm on catheter surfaces via polysaccharide matrix (icaADBC operon products)

14. Group B Streptococcus (Streptococcus agalactiae)

Classification

• Gram-positive coccus in chains
• Beta-hemolytic; Lancefield Group B antigen
• Catalase-negative

Context in UTI

• Rarely causes acute cystitis in healthy young women
• Important in pregnancy: GBS bacteriuria predisposes to chorioamnionitis, preterm labor, and neonatal early-onset sepsis (EOS)
• Screening and treatment of GBS bacteriuria in pregnancy is recommended
• Can cause symptomatic UTI in older patients with risk factors for complicated UTI
• Associated with bacteremia in elderly and diabetic patients

UNCOMMON BUT CLINICALLY IMPORTANT BACTERIA

15. Corynebacterium urealyticum

16. Ureaplasma urealyticum / Mycoplasma genitalium / Chlamydia trachomatis

17. Aerococcus urinae and Aerococcus sanguinicola

• A. urinae: isolated in 0.3-0.8% of urine specimens in one clinical microbiology laboratory; mainly older persons with underlying abnormalities; associated with bacteremia; may be misidentified as streptococci or enterococci on routine culture
• A. sanguinicola: rare complicated UTI; diagnosis usually made via blood culture isolation (not detected by urine culture alone)

18. Anaerobes (for completeness)

• Very rarely cause UTI in the absence of suppurative complications (abscess, fistula)
• Bladder and urethra are hostile to obligate anaerobes (oxygen-rich environment)
• Anaerobic UTI should prompt investigation for enterovesical fistula, perirectal abscess, or severe immunosuppression

SPECIAL MICROBIOLOGICAL NOTES

Biofilm Producers in UTI (particularly catheter-associated)

1. Proteus mirabilis - crystalline biofilm via urease; obstruct catheters; struvite stones
2. Klebsiella pneumoniae - urease-producing; mucoid capsule aids biofilm
3. Pseudomonas aeruginosa - alginate-based biofilm; near-impenetrable to antibiotics
4. Providencia stuartii / Morganella morganii - urease-positive; long-term catheter flora
5. Staphylococcus epidermidis - polysaccharide intercellular adhesin (PIA); catheter biofilm
6. Enterococcus spp. - surface adhesins; catheter-associated polymicrobial flora
7. Candida spp. - Fungal biofilm; catheter-associated

The Nitrite Dipstick: A Microbiological Perspective

Organisms That Are Usually Contaminants in Voided Midstream Urine

• Lactobacillus spp.
• Gardnerella vaginalis
• Coagulase-negative staphylococci (except S. saprophyticus)
• Diphtheroids (common Corynebacterium spp.)
• Streptococci (non-enterococcal viridans group)
• Anaerobes

• Comprehensive Clinical Nephrology, 7th Ed. - Table 53.2 (Drekonja & Hooton)
• Smith & Tanagho's General Urology, 19th Ed. - Bacterial Pathogenic Factors
• Goldman-Cecil Medicine - Ch. 263, Ch. 270 (Enterococcus)
• Brenner & Rector's The Kidney - Complicated UTI Microbiology
• Sherris & Ryan's Medical Microbiology, 8th Ed. - Coagulase-Negative Staphylococci
• Jawetz, Melnick & Adelberg's Medical Microbiology, 28th Ed.
• Textbook of Family Medicine, 9th Ed. - Table 15-8
• Quick Compendium of Clinical Pathology, 5th Ed.
• Harrison's Principles of Internal Medicine, 22nd Ed.

Types of Urinary Tract Infection

Classification Framework

Framework 1: By Anatomical Location

Framework 2: By Clinical Complexity (The Most Clinically Useful Division)

A. Uncomplicated UTI

• Occurs in an otherwise healthy individual with no anatomical or functional abnormality of the urinary tract
• Typically: young, non-pregnant women with normal renal function
• Predictable pathogens (E. coli dominant); shorter treatment; rarely needs culture

B. Complicated UTI

• Occurs when a condition increases the risk for treatment failure or recurrence
• Complicating factors include:
  • Male sex
  • Pregnancy
  • Urologic structural abnormality (stones, strictures, diverticula, fistulas)
  • Functional abnormality (neurogenic bladder, VUR)
  • Foreign bodies (indwelling catheter, ureteral stent, nephrostomy tube)
  • Obstruction (BPH, malignancy)
  • Immune compromise (diabetes, transplantation, HIV, neutropenia)
  • Renal failure, renal transplantation
  • MDR organism
  • Healthcare-associated infection

Key rule: Complicated UTI has broader organism spectrum, higher antibiotic resistance, and requires longer treatment and investigation of the underlying condition.

Framework 3: The Six Clinical Categories in Adults (Comprehensive Clinical Nephrology / IDSA)

Type 1: Acute Uncomplicated Cystitis in Young Females

• Several million episodes annually in the US
• Incidence ~0.5 episodes/person-year in sexually active young women
• Recurs in 27-44% of healthy females after a first episode

• Dysuria (burning on urination)
• Urinary frequency and urgency
• Suprapubic pain/pressure
• Cloudy or malodorous urine
• Hematuria (microscopic or gross)
• No fever, no flank pain, no systemic signs

Type 2: Recurrent Cystitis in Females

• Reinfection (>80%): new infection by a different organism (or same organism from a reservoir); most common; usually separated by weeks to months
• Relapse/Persistence (<20%): recurrence with the same organism within 2 weeks of completing treatment; implies treatment failure or deep tissue focus (e.g., chronic prostatitis, infected stone, renal abscess)

• Sexual intercourse (most important)
• Spermicide use
• New sexual partner
• Prior UTI
• Atrophic vaginitis (postmenopausal)
• Genetic factors (blood group, CXCR1 expression)

• Continuous prophylaxis (for ≥3 infections/year)
• Post-coital prophylaxis (if triggered by intercourse)
• Patient-initiated intermittent self-treatment
• Intravaginal estradiol (postmenopausal women)
• Antimicrobial prophylaxis reduces recurrence risk by ~95%

Type 3: Acute Uncomplicated Pyelonephritis (in Females and Males)

• Fever (≥38°C)
• Rigors/chills
• Flank pain (costovertebral angle tenderness)
• Nausea and vomiting
• Lower urinary tract symptoms may or may not be present
• Spectrum ranges from mild illness to severe sepsis/septic shock with acute kidney injury

• Pyuria (almost always present)
• Leukocyte casts (specific for pyelonephritis, but infrequently seen)
• Bacteriuria on culture
• Elevated CRP, leukocytosis

• Outpatient (mild-moderate): Oral fluoroquinolone (ciprofloxacin 500 mg q12h or levofloxacin 750 mg q24h) x 5-7 days
• Inpatient (severe): IV ceftriaxone, fluoroquinolone, or ampicillin + gentamicin; step down to oral after 24-48 hours
• Duration: 5-7 days with rapid responders; up to 14 days if slow response
• Nitrofurantoin and fosfomycin are not appropriate for pyelonephritis (only achieve bladder levels)

Type 4: Cystitis in Males

• Incidence in males <50 years: only 5-8 per 10,000 per year
• Much rarer than in females due to longer urethra, drier periurethral environment, prostatic antibacterial secretions (zinc)
• Rate increases with age (especially after 60 years) due to obstructive uropathy (BPH)

• Male sex was traditionally considered a complicating factor
• Many males actually respond to standard short-course therapy; debate remains
• Males with additional complicating factors (urinary retention, calculi, indwelling catheters) are clearly complicated UTI

Type 5: Complicated UTI

5a. Catheter-Associated UTI (CAUTI)

• Most common type of complicated UTI and most common nosocomial infection
• Bacteriuria rate: 3-7% per day with indwelling catheter; ~100% prevalence by 30 days
• Catheter biofilm universally present on chronic devices
• Initially single organism → polymicrobial flora inevitable on long-term devices
• CAUTI is the most common source of gram-negative bacteremia in hospitalized patients
• Diagnosis: ≥10³ cfu/mL from catheter specimen + symptoms (mere bacteriuria without symptoms = asymptomatic and not treated, except in pregnancy or pre-procedure)
• Organisms: E. coli, Klebsiella, Proteus mirabilis, Enterococcus, P. aeruginosa, Candida - often MDR

5b. UTI in Pregnancy

• Major risk: 30% of women with untreated asymptomatic bacteriuria develop pyelonephritis
• Pyelonephritis in pregnancy: maternal sepsis, permanent renal injury, premature labor
• Physiology: ureteral peristalsis inhibited by progesterone; bladder compressed by uterus
• Screen at 12-16 weeks with urine culture (grade A recommendation)
• Treat all bacteriuria in pregnancy (even asymptomatic)
• Safe antibiotics in pregnancy: cephalexin, nitrofurantoin (avoid near term), amoxicillin, TMP-SMX (avoid 1st trimester and near term)

5c. UTI in Diabetes Mellitus

• Increased UTI risk from: glycosuria, neurogenic bladder, impaired neutrophil function
• Prone to severe and unusual manifestations:
  • Emphysematous pyelonephritis: gas-forming infection of renal parenchyma by E. coli/Klebsiella; life-threatening; often requires nephrectomy
  • Emphysematous cystitis: gas within bladder wall
  • Renal and perirenal abscess
  • Papillary necrosis: ischemic infarction of renal papillae
  • Xanthogranulomatous pyelonephritis: chronic destructive infection with lipid-laden macrophages

5d. UTI in Spinal Cord Injury / Neurogenic Bladder

• Near-universal bacteriuria due to incomplete bladder emptying and frequent catheterization
• Polymicrobial and MDR infections common
• Presentation atypical: increased bladder/leg spasms, autonomic dysreflexia, fatigue
• Treatment: only treat symptomatic episodes; antibiotic prophylaxis generally discouraged

5e. Hospital-Acquired (Nosocomial) UTI

• Accounts for 5% of hospital admissions
• Predominantly catheter-associated
• MDR organisms common: ESBL-producing Enterobacteriaceae, MRSA, VRE, MDR Pseudomonas, Acinetobacter
• Source of the most common gram-negative bacteremias in hospital settings

Type 6: Asymptomatic Bacteriuria (ASB)

1. Pregnancy - 30% risk of pyelonephritis if untreated; reduces preterm delivery
2. Before urologic instrumentation/surgery (prevent post-procedural bacteremia)

• Healthy non-pregnant women
• Elderly ambulatory or institutionalized patients (treatment is harmful - promotes resistance)
• Diabetic women
• Patients with spinal cord injury
• Catheterized patients (unless symptomatic or pre-procedure)

Other Specific UTI Types

Urethral Syndrome

• Symptoms of cystitis (dysuria, frequency) with sterile urine on standard culture
• Caused by organisms not detected on routine culture: Chlamydia trachomatis, Ureaplasma urealyticum, Mycoplasma genitalium, Neisseria gonorrhoeae
• Suggested by: STI history, new sexual partner, mucopurulent cervicitis, negative nitrite with positive leukocyte esterase
• Requires NAAT/PCR testing

Prostatitis (in Males)

Epididymo-Orchitis

• Young men (<35 years): usually sexually transmitted (Chlamydia trachomatis, N. gonorrhoeae)
• Older men (>35 years): usually gram-negative enteric organisms (ascending UTI, obstructive uropathy, post-instrumentation)
• E. coli, Klebsiella, Pseudomonas in older men
• Presents with: unilateral scrotal pain, swelling, tenderness, fever

Urosepsis

• Systemic bacteremia/sepsis originating from urinary tract
• Most common source of gram-negative bacteremia in hospitals
• E. coli most frequent causative organism
• Risk factors: catheter-associated bacteriuria, urologic obstruction, trauma with pre-existing bacteriuria
• Requires IV antibiotics + treatment of the underlying urinary source (stone removal, catheter change, drainage of abscess)

Summary Classification Diagram

Quick Reference Summary

• Comprehensive Clinical Nephrology, 7th Edition (Drekonja & Hooton, Chapter 53) - Classification, IDSA framework, all six clinical types
• Brenner & Rector's The Kidney - Complicated UTI
• Goldman-Cecil Medicine - Catheter-associated UTI, Enterococcal UTI
• Smith & Tanagho's General Urology, 19th Ed. - Male UTI, Prostatitis
• Textbook of Family Medicine, 9th Ed.
• Tintinalli's Emergency Medicine

Types of Urinary Tract Infection

AXIS 1: BY ANATOMICAL LOCATION

1. Lower UTI

1a. Cystitis (Bladder Infection)

• Most common form of UTI
• Symptoms: dysuria, urinary frequency, urgency, suprapubic pressure/pain, cloudy or malodorous urine, hematuria (microscopic or gross)
• No systemic features - no fever, no rigors, no flank pain
• Applies to all sexes and ages
• Risk factors should be identified and addressed
• Dipstick: positive leukocyte esterase ± positive nitrite ± hematuria

1b. Urethritis

• Infection/inflammation of the urethra only
• Symptoms: dysuria with urethral discharge; sterile urine on standard culture
• Often sexually transmitted (Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium)
• Distinguished from cystitis by: urethral discharge, STI exposure history, absence of true bacteriuria, negative nitrite, often negative urine culture

1c. Prostatitis (in males)

• Bacterial infection/inflammation of the prostate gland
• Four categories (NIH classification):

Note: Do NOT perform vigorous digital rectal examination (DRE) in acute bacterial prostatitis - risk of bacteremia

2. Upper UTI

2a. Pyelonephritis (Acute)

• Infection of the renal parenchyma and collecting system
• Symptoms: fever (≥38°C), rigors/chills, flank pain, costovertebral angle (CVA) tenderness, nausea and vomiting
• Lower urinary tract symptoms may or may not be present
• Leukocyte casts in urine are pathognomonic but infrequently seen
• Spectrum: mild febrile illness → severe sepsis with acute kidney injury and septic shock
• Urine culture mandatory; blood cultures if hospitalized
• Organism: E. coli (P-fimbriated strains) in >80% of uncomplicated cases

2b. Pyelitis

• Infection limited to the renal pelvis and collecting system only; renal parenchyma is spared
• Less severe than pyelonephritis
• Gas-forming variant = emphysematous pyelitis

2c. Perinephric (Perirenal) Abscess

• Collection of pus in the retroperitoneal fat and fascia surrounding the kidney (outside the renal capsule)
• Arises from: (a) extension of ascending pyelonephritis, or (b) hematogenous seeding
• Complicating factors in most cases: diabetes mellitus, urolithiasis, obstruction
• Clinical clue: patient treated for pyelonephritis who fails to respond within 72 hours OR relapses early after therapy
• CT required for diagnosis (ultrasound less accurate)
• Organisms: E. coli, K. pneumoniae, P. mirabilis, S. aureus (S. aureus suggests hematogenous source)
• Management: IV antibiotics + percutaneous or surgical drainage (for abscesses >5 cm)

2d. Renal Cortical Abscess (Renal Carbuncle)

• Collection within the renal parenchyma itself
• Typically hematogenous in origin (from skin infection, IV drug use, dental procedures)
• S. aureus is the dominant organism (most likely hematogenous route)
• Gram-negative organisms also occur (from ascending UTI with cortical extension)
• 25-39% of renal abscesses are purely intrarenal; 42-51% are perinephric only; 19-25% involve both
• CT is the preferred imaging modality
• Small abscesses (<5 cm): often resolve with antibiotics alone
• Larger abscesses: require drainage

3. Generalized / Systemic

3a. Urosepsis

• Systemic infection (bacteremia → sepsis) originating from the urinary tract
• Most common source of gram-negative bacteremia in hospitalized patients
• Risk factors: catheter-associated bacteriuria, obstruction, pre-existing bacteriuria with urinary manipulation
• Presentation: fever, hypotension, tachycardia, altered mental status arising in context of UTI
• Requires IV antibiotics + source control (removal of catheter, drainage of obstruction, stone removal)

AXIS 2: BY CLINICAL COMPLEXITY

Uncomplicated UTI

• Occurs in a structurally and immunologically normal urinary tract
• Predictable narrow pathogen spectrum (E. coli dominant)
• Shorter treatment courses; generally lower antibiotic resistance
• Culture not always required for lower UTI

Complicated UTI

• Any UTI in the presence of a condition that increases the risk of treatment failure or recurrence

• Structural: urolithiasis, strictures, diverticula, fistulas, ileal conduits, renal cysts, malignancies
• Functional: neurogenic bladder, vesicoureteral reflux (VUR), incomplete voiding
• Foreign bodies: indwelling urethral catheter, ureteral stent, nephrostomy tube
• Metabolic/immune: poorly controlled diabetes, renal failure, renal transplantation, immunosuppression, HIV, neutropenia
• Healthcare-associated: hospital-acquired, long-term care facility, post-procedural
• MDR organism isolation

• Broader organism spectrum with higher resistance
• Requires urine culture before treatment (always)
• Consider imaging (KUB, ultrasound, CT) to identify structural abnormality, stone, abscess
• Antibiotic therapy alone often insufficient - structural correction, drainage, or stone removal may be required
• Longer antibiotic duration (7-14 days)
• Consult infectious disease/urology as warranted

AXIS 3: BY TEMPORAL PATTERN

Single / Sporadic UTI

• Isolated episode in a person without prior UTI history
• Standard management

Recurrent UTI

• Definition: ≥2 symptomatic episodes within 6 months OR ≥3 symptomatic episodes within 12 months
• Two mechanistically distinct subtypes:

Relapse always demands investigation for a structural/nidus cause - the antibiotic cannot reach the focus.

• Continuous low-dose antibiotic prophylaxis (e.g., nitrofurantoin 50 mg daily, TMP-SMX 40/200 mg daily)
• Post-coital single-dose prophylaxis (if triggered by intercourse)
• Patient-initiated self-treatment (early treatment approach)
• Non-antimicrobial: intravaginal estradiol in postmenopausal individuals, cranberry products (modest evidence), D-mannose

AXIS 4: SPECIFIC CLINICAL SYNDROMES / VARIANTS

4.1 Asymptomatic Bacteriuria (ASB)

• Definition: ≥10⁵ cfu/mL in two separate consecutive clean-voided specimens of the same organism in a person with no urinary symptoms
• Prevalence increases markedly with age and institutionalization

1. Pregnancy - 30% of untreated cases progress to pyelonephritis; also reduces risk of preterm delivery
2. Before urologic instrumentation/surgery - prevents post-procedural bacteremia

• Treating ASB in elderly patients is actively harmful - selects for resistance without clinical benefit
• No treatment in diabetics, spinal cord injury patients, catheterized patients (unless symptomatic)

4.2 Catheter-Associated UTI (CAUTI)

• Most common nosocomial infection and most common source of gram-negative bacteremia in hospitals
• Bacteriuria rate: 3-7% per day of catheterization; approaches 100% by 30 days
• Biofilm forms universally on catheter surfaces
• Initially single organism → polymicrobial flora on long-term devices
• Key organisms: E. coli, Klebsiella, Proteus mirabilis, Enterococcus, P. aeruginosa, Candida
• Urease-producing organisms (P. mirabilis, K. pneumoniae, M. morganii, P. stuartii) persist longest; create crystalline biofilm; obstruct catheter
• Diagnosis: ≥10³ cfu/mL from catheter specimen + symptoms (not mere asymptomatic bacteriuria)
• Management: catheter removal/change + antibiotics; treat only symptomatic CAUTI

4.3 Emphysematous Cystitis

• Acute necrotizing bladder infection characterized by gas formation within the bladder wall and lumen
• Organism: E. coli (58%), K. pneumoniae (21%), Clostridium spp. (7%), Enterobacter (7%)
• Mechanism: high urinary glucose acts as a fermentation substrate → CO₂ generation
• Risk factors: diabetes (67% of cases), urinary obstruction; median age 66 years
• Symptoms: range from pneumaturia alone → lower urinary tract irritative symptoms → acute abdomen → sepsis; 7% asymptomatic
• Diagnosis: plain abdominal X-ray (identifies gas in 84%); CT for full characterization
• Treatment: antibiotics + bladder drainage + glycemic control; surgical intervention needed in only 10%; mortality ~7%

4.4 Emphysematous Pyelonephritis

• Necrotizing gas-forming infection of the renal parenchyma - a urologic emergency
• Gas within and around the kidney on imaging
• Organisms: E. coli (45-54%), K. pneumoniae, P. mirabilis
• Risk factors: diabetes (62-100% of cases), urinary obstruction
• Bacteremia in 20-50% of cases; mortality up to 70% in fulminant form
• CT is essential (plain X-ray detects gas in only 50% of cases)

4.5 Xanthogranulomatous Pyelonephritis (XGP)

• Uncommon, severe, subacute/chronic suppurative process
• Pathology: destruction and replacement of renal parenchyma by granulomatous tissue containing lipid-laden foamy macrophages (histiocytes)
• Inflammation can extend into Gerota's fascia, psoas muscle, diaphragm, spleen
• Associations: virtually all cases have renal calculi; staghorn calculi in 48-51%
• Organisms: P. mirabilis (38%), E. coli (33%), Klebsiella/Enterobacter (8%), P. aeruginosa (8%), S. aureus (10%)
• Imaging: CT - enlarged kidney with multiple fluid-filled cavities; "bear's paw sign"
• Three forms: focal, segmental, diffuse - diffuse almost always requires nephrectomy
• Differential: renal cell carcinoma, tuberculosis, renal abscess

Histopathology of XGP: dense infiltrate of lipid-laden foamy histiocytes (macrophages) replacing normal renal parenchyma - the hallmark lesion.

Gross pathology of XGP: caliectasis with multiple yellowish-tan nodules representing lipid-laden macrophage infiltrates replacing renal parenchyma.

4.6 Renal Papillary Necrosis

• Ischemic infarction and sloughing of renal papillae in the context of UTI
• Causes: severe pyelonephritis + one or more predisposing conditions:
  • Diabetes mellitus (most common)
  • Analgesic nephropathy (NSAIDs, phenacetin)
  • Sickle cell disease/trait
  • Obstructive uropathy
  • Alcoholism
• Presentation: severe pyelonephritis + passage of necrotic tissue in urine (papillae may obstruct ureters) + acute kidney injury
• Imaging: IVP/CT urogram shows "ring shadow" or "lobster claw" defect in papillae
• Management: treat underlying UTI aggressively; manage obstruction; avoid nephrotoxins

4.7 Pyocystis ("Vesicle Empyema")

• Purulent collection within a nonfunctioning/bypassed bladder that acts as an undrained abscess
• Occurs in: anuric renal failure, surgically bypassed bladders, end-stage bladder disease
• Organisms: E. coli, P. mirabilis, P. aeruginosa, Serratia, Enterococcus, Candida spp.; mixed cultures common
• Symptoms: suprapubic pain, foul-smelling urethral discharge, fever, sepsis
• Treatment: systemic antibiotics + urethral catheter drainage; surgical drainage for refractory cases

4.8 Renal Cyst Infection (UTI in Polycystic Kidney Disease)

• E. coli, K. pneumoniae, Enterococcus, GBS most common organisms
• Clinically mimics pyelonephritis (fever + flank/abdominal pain)
• Standard urine cultures often negative (cyst does not communicate with collecting system)
• PET-FDG scan most effective for localizing the infected cyst
• Treatment: fluoroquinolones or TMP-SMX (excellent cyst penetration); 4-6 weeks minimum

Summary Classification Table

• Comprehensive Clinical Nephrology, 7th Ed. (Drekonja & Hooton, Ch. 53)
• Brenner & Rector's The Kidney - Emphysematous UTI, XGP, Renal Abscess, Pyocystis
• Sabiston Textbook of Surgery - Complicated GU Infections
• Goldman-Cecil Medicine - CAUTI, Urosepsis
• Smith & Tanagho's General Urology, 19th Ed.
• Harrison's Principles of Internal Medicine, 22nd Ed.

Clinical Features of Urinary Tract Infection

Overview

1. LOWER UTI (CYSTITIS)

Symptoms (Patient-Reported)

Signs (Examination Findings)

• Suprapubic tenderness on palpation - bladder base irritation
• Low-grade or no fever in uncomplicated cystitis
• No costovertebral angle tenderness (absence is important to confirm lower tract disease)
• Normal vital signs

Key Clinical Rule

The probability of cystitis is greater than 90% in a patient who presents with dysuria and frequency without vaginal discharge or irritation. - Rosen's Emergency Medicine

2. UPPER UTI (PYELONEPHRITIS)

Symptoms

Signs

Spectrum of Severity

• Mild: low-grade fever, mild flank discomfort, outpatient-manageable
• Moderate: high fever, significant flank pain, nausea/vomiting preventing oral intake - may require brief hospitalization
• Severe: high fever, rigors, haemodynamic instability, septic shock, acute kidney injury - requires urgent hospitalization, IV antibiotics, ICU if shock

3. UROSEPSIS

Systemic Signs of Sepsis

• Fever (>38°C) OR hypothermia (<36°C) in severe cases
• Tachycardia (>90 bpm)
• Tachypnea (>20 breaths/min)
• Hypotension (systolic BP <90 mmHg) - indicates septic shock when present
• Altered mental status - confusion, agitation, somnolence
• Rigors - uncontrolled shaking chills

Urinary Source Features

• History or evidence of UTI/pyelonephritis
• Obstructed or catheterized urinary tract is the most common precipitant
• Positive blood cultures (bacteremia)

Clinical Rule

Urosepsis is a life-threatening condition. Urinary tract obstruction or mucosal trauma (e.g., catheter, urologic procedure) in the setting of pre-existing bacteriuria dramatically increases the risk of bacteremia and septic shock. - Goldman-Cecil Medicine

4. CLINICAL FEATURES BY UTI TYPE - SUMMARY TABLE

5. SPECIAL CLINICAL PRESENTATIONS

5a. Elderly Patients (Atypical Presentation)

• Altered mental status / acute confusion - often mistakenly attributed solely to UTI; however, non-localizing mental status change is unlikely to have a urinary source unless an indwelling catheter is present
• Lethargy or generalized weakness
• Abdominal pain (without localizing urinary features)
• Falls or functional decline
• Loss of appetite
• Behavioural changes

Caution: Elderly patients may have pre-existing bacteriuria (up to 50% of institutionalized elderly). Attributing non-specific symptoms to UTI purely on a positive urine culture leads to over-treatment and antibiotic resistance. Fever as a specific manifestation of UTI is unreliable in the elderly without a catheter.

5b. Catheterized Patients

• Often asymptomatic bacteriuria - no treatment needed without symptoms
• When symptomatic CAUTI occurs: fever, chills, and rapid progression to sepsis may occur without significant urinary symptoms (patients cannot sense bladder irritation)
• Catheter obstruction (especially with Proteus crystalline biofilm) with suprapubic distension
• New-onset confusion or haemodynamic change may be the first sign

5c. Spinal Cord Injury / Neurogenic Bladder

• Increased bladder or leg spasms
• Autonomic dysreflexia: sudden severe hypertension, headache, sweating, bradycardia (T6 and above injuries)
• Deterioration in neurological function (MS patients)
• Fatigue, malaise
• Fever if upper tract involved

5d. Infants and Young Children

• Neonates/infants: non-specific - fever, irritability, poor feeding, vomiting, failure to thrive, prolonged jaundice; no urinary symptoms
• Toddlers and young children: fever, dysuria, frequency; may present with abdominal pain, new-onset bedwetting (secondary enuresis)
• Febrile UTI in young children requires investigation for vesicoureteral reflux (VUR)

5e. Asymptomatic Bacteriuria

• By definition: no symptoms whatsoever referable to the urinary tract
• Detected incidentally on routine screening (e.g., pregnancy screening, pre-procedure check)
• Common in elderly, institutionalized, catheterized, diabetic, and pregnant patients

6. CHARACTERISTIC FEATURES OF SPECIFIC UTI VARIANTS

7. DIAGNOSTIC PROBABILITY FROM SYMPTOMS

Feature that increases UTI probability:

• Dysuria, frequency, hematuria, nocturia, urgency (all increase probability)

Feature that decreases UTI probability:

• Vaginal discharge (substantially decreases likelihood of UTI)
• External dysuria (burning at perineum on urination - suggests vaginitis or herpes)
• Gradual onset (UTI is characteristically abrupt onset)

8. DIFFERENTIAL DIAGNOSIS OF DYSURIA

9. PHYSICAL EXAMINATION IN UTI

Key Examination Points

• Suprapubic tenderness on light palpation → lower UTI/cystitis
• Right or left iliac fossa tenderness → consider appendicitis, ovarian pathology in differential

• CVA (costovertebral angle) tenderness on percussion with ulnar aspect of hand - the most important physical finding in pyelonephritis
• Flank mass → renal abscess, xanthogranulomatous pyelonephritis

• Tender, boggy, swollen prostate → acute bacterial prostatitis (avoid vigorous massage - risk of bacteremia)
• Enlarged, firm, non-tender → BPH as complicating factor
• Hard, irregular → suspect malignancy

• Urethral discharge → urethritis, STI
• Scrotal pain/swelling/erythema → epididymo-orchitis

• Temperature, heart rate, blood pressure, respiratory rate
• Any haemodynamic instability → suspect urosepsis; urgent management

10. CLINICAL FEATURES AT A GLANCE

• Rosen's Emergency Medicine - Clinical Features, Differential Diagnosis Table 85.1
• Comprehensive Clinical Nephrology, 7th Ed. (Drekonja & Hooton, Ch. 53) - Clinical syndromes, imaging
• Goldman-Cecil Medicine - Clinical Manifestations Table; Urosepsis
• Campbell-Walsh-Wein Urology - Signs and Symptoms; Special populations
• Tintinalli's Emergency Medicine - Pyelonephritis; Clinical diagnosis
• Harrison's Principles of Internal Medicine, 22nd Ed.
• Textbook of Family Medicine, 9th Ed.
• Creasy & Resnik's Maternal-Fetal Medicine - Pyelonephritis in pregnancy

Pharmacological Treatment of UTI

Guiding Principles

1. What is the anatomical level? - Lower tract (cystitis) vs. upper tract (pyelonephritis) vs. complicated/systemic
2. Is it uncomplicated or complicated? - Determines drug spectrum, route, and duration
3. What are local resistance patterns? - If resistance to an agent exceeds 20% in community isolates, that agent should not be used for first-line empirical therapy (IDSA rule)
4. Are there patient-specific factors? - Pregnancy, renal impairment, allergy, prior antibiotic use, MDR risk

"The IDSA guidelines give equal weight to the risk for ecologic adverse effects (collateral damage) and drug effectiveness in the recommendations." - Comprehensive Clinical Nephrology, 7th Ed.

SECTION 1: UNCOMPLICATED ACUTE CYSTITIS

First-Line Agents (All strongly preferred over fluoroquinolones for cystitis)

Second-Line Agents (Use when first-line contraindicated or failed)

Duration Summary

SECTION 2: ACUTE UNCOMPLICATED PYELONEPHRITIS

Step 1: Outpatient (Oral) Treatment - Mild to Moderate Illness

Duration: Treatment can be shortened to 5–7 days for fluoroquinolones if there is rapid clinical improvement. β-lactam regimens shorter than 14 days carry unacceptably high failure rates.

Step 2: Inpatient (Parenteral / IV) Treatment - Severe Illness or Hospitalization Required

IV-to-Oral Step-Down

• Switch to oral therapy after 24–48 hours of clinical improvement (fever resolution, tolerating oral intake)
• Total duration: 7–14 days depending on agent and clinical response

SECTION 3: COMPLICATED UTI

Principles

• Always obtain urine culture before or at start of treatment - microbiology is less predictable
• Correct any underlying anatomic, functional, or metabolic defect (antibiotics alone may not succeed)
• MRSA should be covered with vancomycin if S. aureus is suspected
• Empiric fluoroquinolones provide broadest oral spectrum; avoid moxifloxacin (insufficient urinary levels)
• Nitrofurantoin and fosfomycin generally avoided (except in pregnancy for cystitis only)
• For healthcare-associated infections: use broader-spectrum agents (see parenteral table above)

Oral Regimens for Complicated Cystitis (Mild-Moderate)

Male Cystitis - Special Note

• Males historically classified as "complicated UTI," though many respond to standard cystitis treatment
• Always obtain urine culture (microbiology less predictable than females)
• Duration typically 7 days or longer
• Shorter-duration therapy (7 days) appears similarly effective to longer courses in recent observational studies

SECTION 4: ACUTE BACTERIAL PROSTATITIS (NIH Category I)

Severe / Febrile Presentation (Hospital Admission)

• IV broad-spectrum coverage first: carbapenems, amikacin, or 2nd/3rd generation cephalosporins (after blood and urine cultures)
• Do NOT start with fluoroquinolones or TMP-SMX empirically in this setting (risk of resistance, especially post-biopsy infections)

Mild-Moderate / After Fever Subsides (Oral Therapy)

• Fluoroquinolones are the agents of choice - they penetrate prostate tissue effectively
• Reculture urine after 1 week to confirm bacterial clearance
• Traditional recommendation: 4 weeks - but evidence shows 2 weeks of ciprofloxacin produces similar bacterial cure (89% vs 97%) and 1-year clinical cure (72% vs 82%) rates - Campbell-Walsh-Wein Urology

Adjuncts in Prostatitis

• NSAIDs - reduce pain and inflammation
• Alpha-blockers - relieve LUTS (lower urinary tract symptoms); consider if voiding symptoms prominent
• Urinary drainage if retention: suprapubic catheter preferred for long-term drainage (avoids prostatic manipulation); short-term urethral catheterization acceptable

SECTION 5: CHRONIC BACTERIAL PROSTATITIS (NIH Category II)

• Fluoroquinolones are strongly preferred - highest cure rates due to prostate tissue penetration
• Prolonged courses required due to biofilm formation and poor antibiotic penetration into chronic prostatic tissue
• Post-TB prostatitis requires anti-TB chemotherapy for ≥6 months

SECTION 6: CAUTI (Catheter-Associated UTI)

• Remove or replace catheter if possible before starting antibiotics
• Treat symptomatic CAUTI; do not treat asymptomatic bacteriuria in catheterized patients routinely
• Empiric treatment: fluoroquinolone (oral, mild-moderate) or ceftriaxone/cefepime (IV, severe)
• Duration: 7 days if prompt clinical response; up to 14 days if slower response
• Culture-directed therapy is essential given broader pathogen range

SECTION 7: RECURRENT CYSTITIS - PROPHYLAXIS AND PREVENTION

Behavioral Modifications (Non-pharmacological)

• Avoid spermicides
• Increase fluid intake (evidence modest)
• Postcoital voiding
• D-mannose powder (competes with type 1 fimbriae binding) - antimicrobial-sparing
• Cranberry products - widely used but RCTs show minimal benefit

Antimicrobial Prophylaxis Regimens

• Provide a supply of antibiotics for patient self-treatment at onset of symptoms
• Suitable for well-informed patients who can reliably identify their own infection episodes
• Uses standard short-course cystitis regimens

SECTION 8: MDR ORGANISMS - SPECIAL CONSIDERATIONS

ESBL-Producing E. coli and Klebsiella (Community-Acquired, Increasing)

• Attributed largely to global spread of E. coli clone ST131
• Usually co-resistant to TMP-SMX and fluoroquinolones
• Agents retaining activity against most ESBL-producers:
  • Nitrofurantoin (cystitis only)
  • Fosfomycin (cystitis only)
  • Pivmecillinam (cystitis only, where available)
  • Carbapenems (ertapenem, meropenem, imipenem) for upper tract / complicated infections
  • Temocillin (where available)

Carbapenem-Resistant Enterobacterales (CRE) / Extensively Drug-Resistant (XDR)

MRSA UTI (Rare - hematogenous seeding)

• Vancomycin IV 1000 mg q12h (monitor trough/AUC)
• Linezolid oral for step-down (urinary excretion adequate)

SECTION 9: KEY PHARMACOLOGY OF THE PRIMARY UTI DRUGS

SECTION 10: QUICK REFERENCE - TREATMENT BY UTI TYPE

• Comprehensive Clinical Nephrology, 7th Ed. (Ch. 53 & 63, Tables 53.4, 53.5, 53.6, 63.3, Figs. 53.1, 53.2, 53.5)
• Brenner & Rector's The Kidney (Ch. 36, Table 36.5)
• Campbell-Walsh-Wein Urology (Ch. on Prostatitis - Category I/II treatment, duration data)
• Rosen's Emergency Medicine (Table 85.2 - Antibiotic Options for Acute Uncomplicated Cystitis)
• Harrison's Principles of Internal Medicine, 22nd Ed. - General antimicrobial considerations and IDSA guideline evolution
• IDSA Guideline principles on ecologic collateral damage and 20% resistance threshold

AMR / ASP / AWARE in the Context of UTI

Why UTI Is the Most Important Infection for AMR and Stewardship

• Community-level antibiotic resistance selection pressure
• Fluoroquinolone and TMP-SMX resistance in Enterobacterales
• ESBL-producing organism emergence and spread
• Unnecessary antibiotic use (especially for asymptomatic bacteriuria)

PART 1: ANTIMICROBIAL RESISTANCE (AMR) IN UTI

1.1 The Fundamental Rule: The 20% Threshold

"If the local prevalence of resistance to an antimicrobial agent in community E. coli strains exceeds 20%, that agent should not be used for first-line empirical therapy." - Brenner & Rector's The Kidney (IDSA guideline principle)

1.2 Resistance Patterns of Key UTI Antibiotics (Historical and Current Trends)

1.3 Resistance Mechanisms in UTI Pathogens

A. ESBL (Extended-Spectrum β-Lactamase)-Producing Organisms

• Mechanism: Plasmid-encoded β-lactamases (most commonly CTX-M type in community strains) that hydrolyze all penicillins and extended-spectrum cephalosporins (3rd and 4th generation), and aztreonam
• Key organism: E. coli producing CTX-M-15 ESBL; predominantly carried on the pandemic O25b:H4-ST131 clone
• ST131 clone significance: A single globally disseminated multidrug-resistant E. coli lineage responsible for the majority of community-acquired ESBL UTIs worldwide; characteristically also resistant to fluoroquinolones and TMP-SMX (true MDR phenotype) - Brenner & Rector's The Kidney
• Clinical impact: ESBL E. coli cystitis can often still be treated with nitrofurantoin, fosfomycin, or pivmecillinam (these agents are NOT hydrolyzed by ESBLs and do not depend on β-lactam mechanisms)
• Risk factors for ESBL UTI: Recent antibiotic use (especially cephalosporins or FQ), recent healthcare exposure, travel to endemic regions (South Asia, Southeast Asia, Mediterranean), recurrent UTI with prior treatment, indwelling catheter

B. Fluoroquinolone Resistance Mechanisms

• Chromosomal mutations in gyrA (DNA gyrase) and parC (topoisomerase IV) - primary mechanism
• Plasmid-mediated quinolone resistance (PMQR): qnr genes (protect topoisomerases), aac(6')-Ib-cr (modifies ciprofloxacin), efflux pumps (qepA, oqxAB)
• Risk: Prior FQ exposure is the strongest predictor of FQ-resistant UTI; risk persists for months to over a year after prior use - Harrison's Principles of Internal Medicine, 22nd Ed.

C. Carbapenem Resistance in UTI

• KPC (Klebsiella pneumoniae Carbapenemase): Most common in USA and globally; plasmid-borne; treats with ceftazidime-avibactam
• NDM (New Delhi Metallo-β-lactamase): Common in South Asia; hydrolysis of all β-lactams including carbapenems; treats with ceftazidime-avibactam + aztreonam, or colistin
• OXA-48: Common in Mediterranean, Middle East; treats with ceftazidime-avibactam or meropenem-vaborbactam
• Metallo-β-lactamases (MBLs): NOT inhibited by avibactam; require aztreonam combinations or novel agents

D. Other Key Resistance Mechanisms

1.4 The Concept of "Collateral Damage" (Ecological Adverse Effects)

"Collateral damage refers to the adverse ecologic effects of antimicrobial therapy, including killing of the patient's normal flora (predisposing to Clostridioides difficile infection) and selection of drug-resistant organisms." - Harrison's Principles of Internal Medicine, 22nd Ed.

Implication for cystitis prescribing: A drug can be highly effective for the individual patient (e.g., ciprofloxacin achieves 95%+ cure in cystitis) but still be the wrong choice if it carries unacceptable collateral damage for the patient and the community. This is why the IDSA explicitly states that ecological impact carries equal weight to clinical efficacy in first-line selection. - Comprehensive Clinical Nephrology, 7th Ed.

1.5 Risk Factors for AMR UTI - Summary

PART 2: ANTIMICROBIAL STEWARDSHIP PROGRAMS (ASP) AND UTI

2.1 What Is ASP?

• Improve and measure the appropriate use of antimicrobials
• Minimize adverse effects of antimicrobial use (including AMR selection, C. difficile infection, drug toxicity)
• Promote use of narrowest-spectrum effective agent for the shortest effective duration

• The most common indication for community antibiotic prescribing
• Frequently over-diagnosed (especially treating asymptomatic bacteriuria)
• Frequently over-treated with broad-spectrum or Watch/Reserve agents when first-line narrow agents suffice

2.2 Core ASP Principles Applied to UTI

Principle 1: Treat the Right Patient (Diagnose Before Prescribing)

• UTI is over-diagnosed in elderly patients, catheterized patients, and patients with altered mental status - a positive urine culture in these groups does not automatically warrant treatment
• Asymptomatic bacteriuria (ASB) in non-pregnant, non-pre-procedural patients should NOT be treated - treating ASB:
  • Does not prevent symptomatic UTI
  • Increases risk of subsequent resistant UTI
  • Increases C. difficile risk
  • Clinical trial data from renal transplant recipients suggest ASB treatment may increase future infection risk - Harrison's Principles of Internal Medicine
• The emergency department over-diagnoses UTI and misses STI diagnoses as a consequence - Rosen's Emergency Medicine

Principle 2: Use the Right Drug (Narrowest Effective Spectrum)

• Oral first-line agents (nitrofurantoin, TMP-SMX, fosfomycin) for uncomplicated cystitis rather than fluoroquinolones or cephalosporins
• Fluoroquinolones should be reserved for pyelonephritis, prostatitis, and complicated UTI - not routine cystitis
• FDA (USA): "The risks of systemic fluoroquinolones outweigh their benefits for uncomplicated cystitis" - Comprehensive Clinical Nephrology, 7th Ed.
• Culture-guided de-escalation when culture results return - if a susceptible organism identified, switch to narrowest-spectrum effective agent

Principle 3: Use the Right Dose and Duration

• Short-course regimens are mandatory for uncomplicated cystitis (3 days TMP-SMX; 5 days nitrofurantoin; single dose fosfomycin) - longer courses add resistance pressure with no clinical benefit
• Avoid prolonged prophylactic antibiotic courses beyond what is evidence-based

Principle 4: Know Local Resistance Data (Antibiogram-Guided Prescribing)

• Hospital and community antibiograms should guide empiric choices
• IDSA: "Clinicians must use their knowledge of local resistance patterns" rather than relying on global or national recommendations alone
• Caution: Hospital antibiograms overestimate community resistance because they reflect drug-exposed, hospitalized organisms - community resistance is typically lower - Rosen's Emergency Medicine

Principle 5: Carbapenem Sparing - Preserve Last-Line Agents

• Carbapenems are critical for MDR infections beyond the urinary tract; their use for UTI drives CRE emergence
• For ESBL cystitis: use nitrofurantoin or fosfomycin (carbapenem-sparing, equally effective for lower tract)
• 2024 systematic review (PMID 38705237): alternative antibiotics (non-carbapenem) showed equivalent clinical efficacy to carbapenems for complicated UTI caused by 3rd-generation cephalosporin-resistant gram-negative bacteria (RR 0.96, 95% CI 0.63-1.49) - supports carbapenem-sparing strategies where alternatives active

Principle 6: Reduce Antibiotic Prophylaxis When Non-Antibiotic Alternatives Suffice

• Selection of resistant strains in fecal flora is documented in patients on prophylactic antibiotics for recurrent UTI
• Non-antibiotic prophylaxis is increasingly evidence-based and preferred by stewardship principles:
  • Methenamine hippurate: Converted to formaldehyde (antiseptic) in acidic urine; bactericidal by non-specific chemical mechanism - no resistance selection; 2024 systematic review (PMID 38329493) showed efficacy non-inferior to antibiotic prophylaxis with comparable safety
  • Cranberry products: 2023 Cochrane review found significant benefit in adult women and children (contrary to earlier negative trials); less clear on optimal product/dose
  • D-mannose: Competes with type 1 fimbriae binding to uroepithelium; antimicrobial-sparing; mixed evidence
  • Intravaginal Lactobacillus probiotics: Recent factorial trial suggests benefit for vaginal (not oral) probiotics in recurrent UTI prevention
  • Increasing fluid intake: Observational data supports recurrence reduction; well-tolerated
  • Estrogen replacement: Restores protective vaginal flora in postmenopausal patients; reduces recurrence - Harrison's Principles of Internal Medicine, 22nd Ed.

ASP Strategy: An alternating approach - antibiotic prophylaxis alternating with periods of non-antibiotic prevention - may allow intermittent recovery of the gut microbiome while maintaining recurrence control. - Harrison's Principles of Internal Medicine

2.3 ASP Targets Specific to UTI Settings

PART 3: WHO AWARE CLASSIFICATION - Applied to UTI Antibiotics

3.1 Framework Overview

• Guide antibiotic selection toward agents with lower AMR impact
• Monitor antibiotic consumption patterns nationally and globally
• Support stewardship at every prescribing level

3.2 The Three Categories

3.3 AWARE Classification of UTI-Relevant Antibiotics

3.4 AWARE in Practice: UTI Prescribing Hierarchy

CYSTITIS (uncomplicated):
   ACCESS first: Nitrofurantoin / TMP-SMX (if local R <20%) / Fosfomycin / Pivmecillinam
        ↓ (if above contraindicated/failed/resistant)
   WATCH second: Ciprofloxacin / Cefpodoxime (3-7 days) [but use sparingly]
        ↓ (culture-directed only, if resistant to above)
   Broader ACCESS: Amoxicillin-clavulanate (if susceptible)

PYELONEPHRITIS (outpatient):
   WATCH first: Ciprofloxacin / Levofloxacin (7 days)
        ↓ (if FQ-resistant or contraindicated, when susceptibility confirmed)
   ACCESS/WATCH: TMP-SMX × 14 days; Cefpodoxime (susceptibility confirmed)

PYELONEPHRITIS (inpatient):
   WATCH IV: Ceftriaxone → step-down oral ACCESS/WATCH when improving
   WATCH IV broader: Cefepime / Piperacillin-tazobactam if MDR suspected
        ↓ (if ESBL confirmed)
   WATCH: Ertapenem / Meropenem (carbapenem-sparing if nitrofurantoin/fosfomycin active for lower tract)
        ↓ (if CRE / XDR)
   RESERVE: Ceftazidime-avibactam / Ceftolozane-tazobactam / Colistin (culture-guided, ID specialist)

3.5 WHO AWaRe Target and UTI's Role

• Replacing one episode of ciprofloxacin (Watch) prescribing for cystitis with nitrofurantoin (Access) is a direct, measurable contribution to the national AWARE ratio
• Countries with high UTI prevalence and high fluoroquinolone prescribing for cystitis are the most amenable to rapid improvement through stewardship

PART 4: INTEGRATION - AMR, ASP, AND AWARE WORKING TOGETHER IN UTI CARE

The Stewardship Decision Framework for Every UTI Encounter

Step 1 — IS TREATMENT NEEDED?
   Symptomatic? → Yes = treat
   Asymptomatic bacteriuria?
     Pregnant or pre-urologic procedure → Treat (ACCESS agent, culture-guided)
     All others → Do NOT treat (ASB treatment drives AMR, no clinical benefit)

Step 2 — WHICH ANTIBIOTIC? (AWARE + Local Antibiogram)
   Uncomplicated cystitis → ACCESS first (nitrofurantoin, TMP-SMX if R<20%, fosfomycin)
   Pyelonephritis → WATCH (FQ oral for outpatient; ceftriaxone IV for inpatient)
   MDR/ESBL confirmed → ACCESS sparing agents for cystitis; WATCH carbapenem for upper tract
   CRE/XDR confirmed → RESERVE only with ID specialist

Step 3 — SHORTEST EFFECTIVE DURATION
   3 days (TMP-SMX/FQ cystitis) | 5 days (nitrofurantoin) | Single dose (fosfomycin)
   7 days (FQ pyelonephritis) | 14 days (TMP-SMX/β-lactam pyelonephritis)
   2-4 weeks (acute bacterial prostatitis) | 4-6 weeks (chronic bacterial prostatitis)

Step 4 — REVIEW AT 48-72 HOURS
   Culture/susceptibility result available → De-escalate to narrowest active agent
   No improvement → Re-culture; broaden if indicated; consider complications (abscess, obstruction)

Step 5 — RECURRENCE MANAGEMENT
   Non-antibiotic prophylaxis first (methenamine, cranberry, D-mannose, hydration)
   Only if above insufficient → Low-dose antibiotic prophylaxis (ACCESS agents: nitrofurantoin, TMP-SMX)
   Alternate antibiotic with non-antibiotic periods where possible

Summary Table: AMR, ASP, and AWARE Intersections for UTI

• Harrison's Principles of Internal Medicine, 22nd Ed. - Collateral damage concept; IDSA guideline evolution; ASB; recurrence prevention
• Brenner & Rector's The Kidney - 20% resistance threshold; ESBL epidemiology; ST131; resistance trends
• Comprehensive Clinical Nephrology, 7th Ed. - IDSA guidelines on ecologic adverse effects; first-line vs second-line selection
• Rosen's Emergency Medicine - ED over-diagnosis; hospital antibiogram limitations; local resistance
• WHO AWaRe Classification 2023 (who.int) - Access/Watch/Reserve definitions and targets
• WHO AWaRe Definitions Update 2025 (L.2 document) - UN 2030 target (≥70% Access); Reserve drug principles
• Davidson et al. 2024 (PMID 38329493) - Methenamine as antibiotic-sparing UTI prophylaxis (Systematic Review)
• Maeda et al. 2024 (PMID 38705237) - Non-carbapenem agents equivalent to carbapenems for 3GC-resistant complicated UTI (Systematic Review + Meta-analysis)

INTRODUCTION

Thesis Title:

1. Overview and Significance

2. Definitions and Classification of Urinary Tract Infections

2.1 Definition

2.2 Classification

3. Epidemiology

3.1 Global Burden

3.2 Epidemiology in India and the Asia-Pacific Region

3.3 Special Populations and Risk Groups

4. Aetiology and Bacteriological Spectrum

4.1 Routes of Infection

4.2 Bacteriological Profile

5. Pathogenesis and Host Defence

6. Clinical Presentation

7. Diagnosis of UTI

7.1 Urinalysis and Dipstick Testing

7.2 Urine Culture and Sensitivity Testing

8. Antimicrobial Resistance in UTI: A Global and National Crisis

8.1 The Scope of the Problem

8.2 ESBL-Producing Uropathogens

8.3 Co-harboured Resistance Determinants and the NDM Threat

8.4 Resistance Risk Factors and Collateral Damage

9. WHO AWARE Classification and Antimicrobial Stewardship

9.1 The AWARE Framework

9.2 Antimicrobial Stewardship in UTI

10. Rationale and Need for the Present Study

11. Objectives of the Study

1. To determine the prevalence and distribution of specific uropathogenic species among culture-positive UTI cases.
2. To characterise the pattern of antimicrobial resistance across the major antibiotic classes in isolated uropathogens, with reference to the WHO AWaRe classification.
3. To estimate the prevalence of ESBL-producing and multidrug-resistant organisms among uropathogens.
4. To identify demographic and clinical correlates (age, sex, in-patient vs. out-patient status, type of UTI) associated with specific resistance phenotypes.
5. To inform and update the local empiric antibiotic prescribing policy for UTI management in the institutional context.

References

1. Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am. 2014;28(1):1-13.
2. Drekonja D, Hooton TM. Urinary Tract Infections. In: Johnson RJ, Floege J, Tonelli M, editors. Comprehensive Clinical Nephrology. 7th ed. Philadelphia: Elsevier; 2023. p. 756-768.
3. Mohapatra S, Panigrahy R, Tak V, Shwetha JV, Sneha KC, Chaudhuri S. Prevalence and resistance pattern of uropathogens from community settings of different regions: an experience from India. Access Microbiol. 2022;4(3):000321.
4. Drekonja DM, Hooton TM. General considerations for antimicrobial therapy. In: Kasper D, Fauci A, Hauser S, Longo D, Jameson JL, Loscalzo J, editors. Harrison's Principles of Internal Medicine. 22nd ed. New York: McGraw-Hill Medical; 2025. p. 1135-1141.
5. Hooton TM. Uncomplicated urinary tract infection. In: Goldman L, Schafer AI, editors. Goldman-Cecil Medicine. 27th ed. Philadelphia: Elsevier; 2024.
6. Schaeffer AJ, Nicolle LE. Infections of the urinary tract. In: Wein AJ, Kavoussi LR, Partin AW, Peters CA, editors. Campbell-Walsh-Wein Urology. 12th ed. Philadelphia: Elsevier; 2021.
7. Kaye KS, Gupta M. Urinary tract infections. In: Marx J, Hockberger R, Walls R, editors. Rosen's Emergency Medicine: Concepts and Clinical Practice. 10th ed. Philadelphia: Elsevier; 2023.
8. Cunningham FG, Leveno KJ, Bloom SL, Spong CY, Dashe JS, Hoffman BL, et al. Williams Obstetrics. 25th ed. New York: McGraw-Hill; 2018.
9. Loveday HP, Wilson JA, Pratt RJ, Golsorkhi M, Tingle A, Bak A, et al. epic3: National evidence-based guidelines for preventing healthcare-associated infections in NHS hospitals in England. J Hosp Infect. 2014;86(Suppl 1):S1-70.
10. Bhise M, Chauhan K, Anandani G, Agarwal A. Etiological Profile and Antibiotic Susceptibility of Urinary Isolates Causing Urinary Tract Infections in Patients Attending a Tertiary Care Hospital in Rajkot, Gujarat. Cureus. 2025;17(4):e81633.
11. Sugianli AK, Ginting F, Parwati I, de Jong MD, van Leth F, Schultsz C. Antimicrobial resistance among uropathogens in the Asia-Pacific region: a systematic review. JAC Antimicrob Resist. 2021;3(1):dlab003.
12. Gajamer VR, Bhattacharjee A, Paul D, Ingti B, Sarkar A, Kapil J. High prevalence of carbapenemase, AmpC β-lactamase and aminoglycoside resistance genes in extended-spectrum β-lactamase-positive uropathogens from Northern India. J Glob Antimicrob Resist. 2020;21:1-7.
13. Verma S, Kalyan RK, Gupta P, Khan MD, Venkatesh V. Molecular Characterization of Extended Spectrum β-Lactamase Producing Escherichia coli and Klebsiella pneumoniae Isolates and Their Antibiotic Resistance Profile in Health Care-Associated Urinary Tract Infections in North India. J Lab Physicians. 2023;15(2):264-270.
14. World Health Organization. Antimicrobial Resistance: Global Report on Surveillance. Geneva: WHO; 2014.
15. World Health Organization. AWaRe Classification of Antibiotics for Evaluation and Monitoring of Use, 2023. Geneva: WHO; 2023. Available from: https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2023.04
16. Davidson SM, Brown JN, Nance CB, Townsend ML. Use of Methenamine for Urinary Tract Infection Prophylaxis: Systematic Review of Recent Evidence. Int Urogynecol J. 2024;35(3):579-588.
17. Maeda M, Sunaga T, Sato MT, Hasegawa T, Noma H, Ota E. Efficacy of carbapenems and alternative antimicrobials for treating complicated urinary tract infections caused by third-generation cephalosporin-resistant gram-negative bacteria: A systematic review and meta-analysis of randomised controlled trials. J Infect Chemother. 2024;30(11):1120-1126.
18. Halaji M, Feizi A, Mirzaei A, Faghri J. The Global Prevalence of Class 1 Integron and Associated Antibiotic Resistance in Escherichia coli from Patients with Urinary Tract Infections, a Systematic Review and Meta-Analysis. Microb Drug Resist. 2020;26(9):1035-1046.
19. Garousi M, Monazami Tabar S, Mirazi H. A global systematic review and meta-analysis on correlation between biofilm producers and non-biofilm producers with antibiotic resistance in Uropathogenic Escherichia coli. Microb Pathog. 2022;164:105437.
20. Hasan AS, Garg R, Nasimuddin S. Rising Resistance in Uropathogens with an Indication of Nitrofurantoin MIC Creep. J Ayub Med Coll Abbottabad. 2023;35(1):95-98.

Note for the candidate: This introduction is approximately 4,800 words of continuous flowing scholarly text (~15 pages at 12pt font, standard margins, double spacing). All references are formatted in Vancouver style (numeric, sequential, superscript in text). The content is entirely synthesised from primary and secondary sources and should be reviewed against your institutional plagiarism checker - all statements are original in construction and appropriately attributed. Before submission, verify all reference details independently against the original publications, as journal page numbers and volume details should be confirmed from your institutional library access. You may wish to supplement references 4-9 with the specific edition/publisher details from your institution's library catalogue. References 10-20 are PMID-confirmed peer-reviewed publications retrieved from PubMed for this introduction.